Skip to Content
Merck

In vitro susceptibilities of Mycoplasma putrefaciens field isolates.

Antimicrobial agents and chemotherapy (2007-07-20)
N T Antunes, M M Tavío, P Mercier, R D Ayling, W Al-Momani, P Assunção, R S Rosales, J B Poveda
ABSTRACT

MICs were determined for 15 antimicrobial agents against 37 Mycoplasma putrefaciens isolates. The most effective antimicrobial drug classes were the fluoroquinolones, the tetracyclines, the lincosamide lincomycin, and the macrolides. The susceptibility profile of the isolates correlated with the geographic origin. This is the first report of decreased susceptibility to the macrolides, lincomycin, and the tetracyclines in M. putrefaciens strains.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Erythromycin, tested according to Ph. Eur.
Sigma-Aldrich
Erythromycin, potency: ≥850 μg per mg
Sigma-Aldrich
Erythromycin, BioReagent, suitable for cell culture
Sigma-Aldrich
Erythromycin, meets USP testing specifications
Supelco
Ciprofloxacin, VETRANAL®, analytical standard
Supelco
Enrofloxacin, VETRANAL®, analytical standard
Supelco
Norfloxacin, VETRANAL®, analytical standard
Sigma-Aldrich
Enrofloxacin, ≥99.0%
Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)
Sigma-Aldrich
Nalidixic acid, ≥98%
Supelco
Norfloxacin, analytical standard, ≥98% (TLC)